Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma
Keiichiro Yokota(Kochi Medical School Hospital), Tetsuji Naka(Iwate Medical University), Minoru Fujimoto(Iwate Medical University), Tsutomu Namikawa(Kochi Medical School Hospital), Keisuke Toya(Osaka Gakuin University), Yuichiro� Doki(Osaka Gakuin University), Kazuhiro Hanazaki(Kochi Medical School Hospital), Hidetoshi Eguchi(Osaka Gakuin University), Ichiro Murakami(Kōchi University), Takashi Matsunaga(Shiga University of Medical Science), Sunao Uemura(Kochi Medical School Hospital), Shigehiro Tsujii(Kochi Medical School Hospital), Satoshi Serada(Iwate Medical University), Tsuyoshi Takahashi(Osaka Gakuin University), Shogo Kobayashi(Osaka Gakuin University)
Cited by 24
Related Papers
The paradigm of IL-6: from basic science to medicine.
|Arthritis Research|2002|481
Validation of A New Prognostic Staging System for Hepatocellular Carcinoma: the Jis Score Compared With the Clip Score
|Hepatology|2004|359
A novel image‐guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation
|Journal of Surgical Oncology|2009|333
Overexpression of miR-200c Induces Chemoresistance in Esophageal Cancers Mediated Through Activation of the Akt Signaling Pathway
|Clinical Cancer Research|2011|245
Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)
|Journal of Hepato-Biliary-Pancreatic Sciences|2022|244